Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-Arm Study of Nivolumab in Classical Hodgkin Lymphoma
2014-001509-42Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in classical Hodgkin lymphoma (cHL) (4 cohorts), sponsored by Bristol Myers Squibb. Primary endpoint: Best overall response rate (CR or PR) in cohorts A, B, and C. Started Jun 2014; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2014-001509-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001509-42.